- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Justify proposed dosage and high strength with data: CDSCO Panel Tells Hetero Healthcare on Tioconazole vaginal film 300 mg
New Delhi: Noting Tioconazole Vaginal Film 300mg is not approved anywhere in the world, the Subject Expert Committee SEC functional under the Central Drug Standard Control Organisation (CDSCO) has opined Hetero Healthcare to submit adequate rational/justification for the development of the proposed dosage form in such high strength along with release pattern data of the proposed formulation, adequate toxicity data, anticipated side effects, and supportive clinical evidence of the proposed dosage form to CDSCO for further review by the committee.
This came after Hetero Healthcare presented the proposal for manufacturing and marketing of Tioconazole Vaginal Film 300 mg along with Phase III protocol (Protocol No. HHCL/01-01/24 version 1.0 dated 18/01/2024) before the committee.
The committee noted that Tioconazole Vaginal Film 300mg is not approved anywhere in the world. However, Ticonazole vaginal gel 65mg/gm is approved in India on dated 22.03.2011. However, Ticonazole vaginal gel 65mg/gm is approved in India on dated 22.03.2011.
The committee further noted that the justification for using the reference drug, Canesten V6 (Clotrimazole) vaginal tablet 100 mg, is not adequate when the dosage form of Ticonazole is available.
In addition to the above, the committee also mentioned that the applied dose is 5-fold higher than the approved dose (Ticonazole vaginal gel 65 mg/g). The committee urged that preclinical data and vaginal toxicity data should support such a higher dose.
Tioconazole is an imidazole antifungal used to treat fungal and yeast infections. Topical formulations are used for ringworm, jock itch, athlete's foot, and tinea versicolor or "sun fungus". Tioconazole interacts with 14-alpha demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane. In this way, tioconazole inhibits ergosterol synthesis, resulting in increased cellular permeability.
At the recent SEC meeting for antimicrobial and antiviral held on 22nd August 2024, the expert panel reviewed the proposal for manufacturing and marketing of Ticonazole Vaginal Film 300 mg along with Phase III protocol (Protocol No. HHCL/01-01/24 version 1.0 dated 18/01/2024) before the committee.
After detailed deliberation, the committee opined that the firm should submit adequate rationale/justification for the development of the proposed dosage form in such high strength along with release pattern data of the proposed formulation, adequate toxicity data, anticipated side effects, and supportive clinical evidence of the proposed dosage form to CDSCO for further review by the committee.
Also Read:Bristol Myers Squibb India Gets CDSCO Panel Nod to Study anticancer drug Mezigdomide
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751